What Is Included in a Hepatic Function Panel?

A hepatic function panel is a group of blood tests that measures enzymes, proteins, and waste products to assess how well your liver is working. The standard panel typically includes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, and total protein. Some labs also add direct bilirubin and gamma-glutamyltransferase (GGT), though the exact lineup varies by institution. Despite its name, the panel does not test liver “function” in a single neat number; each component tells a different part of the story, and the real clinical value lies in how the results relate to one another.

The Aminotransferases: ALT and AST

ALT and AST are the two enzymes most people think of when they hear “liver tests.” Both are released into the bloodstream when liver cells are damaged or inflamed, so elevated levels signal that something is injuring the liver. ALT is considered more liver-specific because it is found predominantly in liver cells, whereas AST also lives in heart muscle, skeletal muscle, kidneys, and red blood cells. That distinction matters: a high AST with a normal ALT might point away from the liver entirely.

These two markers are the workhorses of liver injury detection, but they come with real limitations. Both have poor prognostic value in acute liver failure, meaning a sky-high ALT does not reliably predict whether someone will recover or deteriorate.¹ They tell you damage is happening but not how much functional liver tissue remains. Think of them as smoke detectors: they alert you to a fire but cannot tell you how much of the house is still standing.

The ratio between AST and ALT, sometimes called the De Ritis ratio, adds another layer of information. In most chronic liver diseases, ALT tends to be higher than AST. But when AST overtakes ALT, it can signal more advanced damage such as fibrosis or cirrhosis. This shift partly reflects the biology of the enzymes themselves: AST clears from the blood faster than ALT, so a persistently high AST suggests ongoing, aggressive injury.² Doctors use this ratio alongside other findings rather than as a standalone diagnostic tool.

Alkaline Phosphatase and GGT

Alkaline phosphatase (ALP) is an enzyme found in the cells lining the bile ducts inside the liver. When bile flow is obstructed or slowed, ALP rises. Gallstones blocking the common bile duct, tumors pressing on bile passages, and certain medications can all drive ALP up. The catch is that ALP is not exclusive to the liver. It is also produced by bone, the intestines, the placenta, and the kidneys. A teenager going through a growth spurt or someone with a healing fracture can have elevated ALP that has nothing to do with liver disease.

This is where GGT becomes useful. GGT is another enzyme concentrated in bile duct cells, but unlike ALP, it does not rise with bone activity. When ALP is elevated on its own, measuring GGT can clarify whether the source is the liver or somewhere else.³ If both ALP and GGT are high, the liver is the likely culprit. If ALP is high but GGT is normal, your doctor will look at bone or other non-hepatic causes. GGT also rises with heavy alcohol use, which makes it a useful (though imperfect) marker in that context.

Bilirubin

Bilirubin is the yellowish pigment produced when your body breaks down old red blood cells. The liver processes bilirubin in two stages. First, unconjugated (indirect) bilirubin arrives at the liver via the bloodstream. The liver then attaches a sugar molecule to it, creating conjugated (direct) bilirubin, which is water-soluble and can be excreted into bile. A standard hepatic function panel reports total bilirubin, and many labs also report direct bilirubin separately.

Elevated total bilirubin can mean different things depending on whether the direct or indirect fraction is driving it up. A rise in indirect bilirubin often points to problems before the liver, such as excessive red blood cell destruction. A rise in direct bilirubin suggests the liver is conjugating bilirubin normally but cannot excrete it, which happens with bile duct obstruction or significant liver cell damage. In people with cirrhosis, direct bilirubin has been shown to be a stronger predictor of short-term outcomes than total bilirubin alone.⁴

When bilirubin accumulates enough, you see it: the whites of the eyes turn yellow first, followed by the skin. That visible yellowing, called jaundice, typically appears when total bilirubin exceeds roughly two to three times the upper limit of normal. Mild elevations without jaundice are common and often benign. Gilbert syndrome, a harmless genetic variation affecting bilirubin processing, causes mildly elevated indirect bilirubin in roughly 5 to 10 percent of the population and rarely needs treatment.

Albumin and Total Protein

While the enzymes and bilirubin reflect damage or obstruction, albumin measures the liver’s manufacturing ability. The liver produces about 10 to 11 grams of albumin per day, with a turnover time of roughly 25 days.⁵ Because albumin sticks around in the blood for weeks, a drop in albumin signals that the liver has been underperforming for a while rather than suffering a sudden insult. Acute hepatitis can produce dramatic enzyme spikes while albumin stays normal, simply because there is still plenty of previously made albumin circulating.

Low albumin is a hallmark of chronic liver disease, but it is not specific to the liver. Kidney disease, malnutrition, chronic inflammation, and even prolonged bed rest can drag albumin down. That is why doctors interpret it alongside the rest of the panel rather than in isolation.⁵ Total protein, which combines albumin with globulins and other proteins, rounds out this picture. A low total protein with low albumin suggests the liver is not making enough protein overall. A normal total protein with low albumin can mean that globulins are elevated, pointing toward chronic infection, autoimmune disease, or certain cancers.

Research on liver disease consistently shows that albumin and the albumin-to-globulin (A/G) ratio drop significantly as disease severity increases.⁶ This makes them useful staging markers when tracked over time.

How Doctors Read the Pattern

No single test on the panel gives a diagnosis. The value is in the pattern. Clinicians generally sort abnormal results into one of three categories: hepatocellular injury, cholestatic injury, or mixed.

• Hepatocellular: ALT and AST are disproportionately elevated compared to ALP. This pattern suggests direct liver cell damage from causes like viral hepatitis, alcohol, medications, or autoimmune hepatitis.
• Cholestatic: ALP is disproportionately elevated compared to ALT. This pattern points toward bile duct obstruction or diseases affecting bile flow, such as gallstones, primary biliary cholangitis, or tumors.
• Mixed: Both enzymes and ALP are elevated without a clear dominant pattern, which can occur with drug reactions, infiltrative diseases, or some infections.

A more formal way to distinguish these patterns uses the ratio of ALT elevation to ALP elevation, each expressed as a multiple of its upper limit of normal. When that ratio is five or higher, the pattern is hepatocellular. When it is two or lower, it is cholestatic. Anything in between is considered mixed.⁷ This classification is especially important when investigating drug-induced liver injury, because the pattern helps narrow down which medication is the likely offender and guides treatment decisions.

Bilirubin and albumin then add context to the pattern. High enzymes with normal bilirubin and normal albumin usually mean mild or early disease. High enzymes paired with rising bilirubin or falling albumin suggest more serious or chronic damage. When the panel comes back abnormal, ultrasound is often the first imaging step, particularly to check for bile duct dilation or masses.⁸

When Exercise Fakes Liver Disease

One of the most common reasons for unexpectedly abnormal liver tests has nothing to do with the liver at all. Strenuous exercise, particularly resistance training and endurance events, can spike AST and ALT enough to alarm both patients and doctors. In one study, healthy men who performed intense weightlifting had significantly elevated AST and ALT for at least seven days afterward.⁹ Creatine kinase and myoglobin, which are muscle-specific markers, were also sky-high, confirming that the source was muscle breakdown rather than liver injury.

Endurance exercise produces similar effects. After a half-marathon, runners showed significant increases in GGT, AST, bilirubin, and other markers typically associated with liver damage. Some of these elevations persisted for at least 24 hours after the run.¹⁰ If you are a regular exerciser and your doctor orders liver tests, mention your workout schedule. Ideally, avoid heavy exercise for a few days before the blood draw. Otherwise, you may end up chasing a liver problem that does not exist.

Medications That Move the Needle

Dozens of common medications can cause mild or moderate elevations in liver enzymes, and this creates a frequent clinical puzzle. Statins, the cholesterol-lowering drugs taken by tens of millions of people, have probably generated more worry about liver tests than any other drug class. Mild aminotransferase elevations occur in a small percentage of statin users, and the pattern is usually hepatocellular. Rarely, more serious liver injury with autoimmune features has been reported.¹¹

The practical takeaway for statin users has evolved over the years. The FDA changed statin labeling in 2012 to reflect a more relaxed approach: a baseline liver test before starting therapy is appropriate, but routine monitoring while on the medication is no longer recommended. Liver tests should be checked only if new signs or symptoms of liver disease appear.¹² Other medications commonly associated with liver enzyme elevations include acetaminophen (especially at high doses or combined with alcohol), certain antibiotics, antifungals, anti-seizure drugs, and some herbal supplements. If you are on any of these and see an abnormal panel, your provider will weigh the timing, the pattern, and whether the elevation resolves when the drug is stopped.

Pregnancy Changes the Reference Ranges

Pregnancy reshapes liver test results in ways that can confuse interpretation. Abnormal liver tests show up in roughly 3 to 5 percent of pregnancies.¹³ Some of these abnormalities reflect normal physiology rather than disease. The increased blood volume of pregnancy dilutes albumin, so serum albumin levels run lower across all three trimesters.¹⁴ ALP rises substantially in the third trimester because the placenta produces its own version of the enzyme. Meanwhile, bilirubin and GGT actually tend to decrease during the second and third trimesters.¹⁴

These normal shifts matter because pregnancy also carries risks for genuine liver conditions, including preeclampsia with liver involvement, HELLP syndrome, intrahepatic cholestasis of pregnancy, and acute fatty liver of pregnancy. All of these are potentially serious and require prompt diagnosis. The challenge is distinguishing normal pregnancy-related changes from pathological ones. A high ALP in the third trimester may be the placenta doing its job, but a high ALP combined with elevated bile acids and itching suggests intrahepatic cholestasis and warrants immediate evaluation.¹⁵ Providers caring for pregnant patients need to interpret the panel against pregnancy-adjusted norms rather than standard adult ranges.

Why Children Need Their Own Reference Ranges

Standard adult reference ranges printed on a lab report do not apply to children, and using them can lead to missed diagnoses or unnecessary alarm. Liver chemistry values in children shift substantially with age and, for some markers, diverge by sex during puberty. A large study of healthy children aged 0 to 18 found that the 97.5th percentile for ALT in males increased from 34 IU/L at age five to 63 IU/L by age 18, while the median AST steadily decreased with age in both sexes. ALP fell after age nine, and total bilirubin rose with age.¹⁶ Despite these substantial shifts, the reference ranges printed by most labs change minimally across pediatric age groups, which means they can underestimate or overestimate what is truly abnormal for a given child.

A study establishing pediatric reference intervals for a Han Chinese population found that AST alone required seven different age- and gender-specific partitions to capture normal variation accurately, while albumin needed only two.¹⁷ Newborns and young infants are a special case: ALT and ALP tend to be markedly higher in the first few months of life, and total bilirubin starts high (an average of about 1.64 mg/dL in early life) before dropping by roughly half in the next age window.¹⁸ If your child’s liver panel comes back with a flagged value, it is worth asking whether the lab used age-appropriate cutoffs.

What the Panel Does Not Tell You

For all its usefulness, the hepatic function panel has blind spots. It cannot stage fibrosis or cirrhosis on its own. Someone with well-compensated cirrhosis may have a near-normal panel because the remaining healthy liver tissue is still managing to keep up. Conversely, a dramatic spike in ALT from a brief, self-limited viral infection can look terrifying on paper while the liver fully recovers within weeks.

The panel also cannot identify the cause of liver disease. An elevated ALT tells you liver cells are being damaged, but not whether the culprit is alcohol, a virus, an autoimmune process, fat accumulation, or a medication. That requires additional tests: viral hepatitis serologies, autoimmune antibodies, iron studies, imaging, and sometimes biopsy. The hepatic function panel is a screening and monitoring tool, not a diagnostic endpoint. It tells your doctor something may be wrong and helps shape which direction to investigate, but rarely provides the final answer by itself.

Prothrombin time (PT) and the international normalized ratio (INR) are sometimes grouped with the hepatic function panel in clinical practice, though they are technically separate coagulation tests. Because the liver manufactures most clotting factors, a prolonged PT or elevated INR can be an early sign that the liver’s synthetic capacity is failing. If your provider orders a “comprehensive liver panel,” these coagulation markers may be included alongside the standard components.